CE-031 is a soluble form of the activin type IIB receptor and is known to bind to myostatin and neutralize its effects.
CAT No: 10-101-315
CAS No:1621169-52-5
Synonyms/Alias:UNII-U8DGS69FVC;Myostatin inhibitory peptide 7;1621169-52-5;U8DGS69FVC;CHEMBL3410227;Ala-Trp-Arg-Gln-Asn-Thr-Arg-Tyr-Ser-Arg-Ile-Glu-Ala-Ile-Lys-Ile-Gln-Ile-Leu-Ser-Lys-Leu-Arg-Leu-NH2;BDBM50071379;ACE-031 Myostatin inhibitory peptide 7;
ACE-031; Myostatin inhibitory peptide 7 is a synthetic peptide compound designed to modulate the activity of myostatin, a critical regulator of skeletal muscle growth and differentiation. As a biochemically engineered ligand trap, it functions by binding to and neutralizing myostatin, thereby interfering with its ability to inhibit muscle development. This property positions the peptide as a valuable research tool in studies exploring the molecular mechanisms of muscle physiology, signaling pathways involved in muscle homeostasis, and the broader regulation of tissue growth. The peptide's specificity and potency make it especially relevant for experimental applications where precise modulation of myostatin activity is required for mechanistic insight or functional analysis.
Muscle biology research: In the context of muscle biology, ACE-031; Myostatin inhibitory peptide 7 serves as a robust molecular probe for dissecting the role of myostatin in muscle cell proliferation, differentiation, and hypertrophy. Researchers utilize the peptide to experimentally suppress myostatin signaling in cultured myoblasts or animal models, enabling the study of downstream genetic and phenotypic effects. Such investigations are fundamental for elucidating the cellular and molecular processes governing muscle growth, atrophy, and regeneration.
Signal transduction studies: The peptide is widely applied in the analysis of intracellular signaling cascades downstream of myostatin inhibition. By selectively blocking myostatin activity, scientists can monitor alterations in the SMAD signaling pathway, assess the cross-talk with other growth factors, and map the transcriptional networks responsible for muscle-specific gene expression. These studies contribute to a more comprehensive understanding of TGF-β superfamily signaling and its influence on cellular fate decisions.
Protein interaction assays: ACE-031; Myostatin inhibitory peptide 7 is instrumental in binding studies aimed at characterizing the interaction dynamics between myostatin and its endogenous receptors, such as activin receptor type IIB. Through competitive binding assays and surface plasmon resonance experiments, the peptide enables quantitative assessment of affinity, specificity, and inhibitory kinetics. These data facilitate structure-activity relationship analyses and support the rational design of next-generation myostatin antagonists.
In vitro muscle modeling: The inhibitory peptide is frequently incorporated into in vitro muscle tissue models to simulate altered myostatin environments. By modulating the balance of growth-promoting and inhibitory signals, researchers can recapitulate physiological or pathological conditions relevant to muscle wasting, hypertrophy, or adaptation. Such models are essential for screening compounds that impact muscle mass and for validating hypotheses regarding muscle plasticity under various biochemical stimuli.
Peptide-based drug discovery: While not intended for clinical or therapeutic use, ACE-031; Myostatin inhibitory peptide 7 plays a pivotal role in early-stage drug discovery pipelines focused on myostatin modulation. Its well-characterized activity profile makes it a reference compound for benchmarking novel peptide analogs, small molecule inhibitors, or biologics targeting the myostatin axis. Comparative studies using this peptide inform lead optimization strategies and help establish the pharmacological parameters required for effective myostatin inhibition in preclinical research settings.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More